Job title: Principal Scientist
Julie Bailis, PhD, is a Principal Scientist in Oncology Research at Amgen. Julie’s team is responsible for the discovery and development of novel oncology therapeutics, from target identification and validation through support for first in human clinical studies. Her research over the past six years has centered on bispecific T-cell engager antibody constructs for solid tumors. Julie was a Damon Runyon postdoctoral fellow at the Salk Institute for Biological Studies, where her work focused on the DNA damage response and mechanisms of genome instability in cancer. She obtained her PhD in Molecular and Cellular Biology from Yale University.
Panel Discussion: Focusing on Dosing Regimens and the Therapeutic Window in order to Develop Easily Administered Drugs 2:15 pm
• Exploring the potential ability of drugs with short serum half-lives allowing precise control of drug levels within the patient to enhance their potential safety • Determining the exposure levels needed for cell engagers to be effective • Understanding the importance of dose selection and escalation • What preclinical information is actually useful? • Do…Read more
day: Day Two
Rational Combinations for Bispecific T-cell Engager (BiTE®) Immune Therapy in Solid Tumors 12:00 pm
day: Day Two